Keywords: oncology, update, brief, phase, ii, trial, high-dose
Oncology Update In Brief
Article | 08 December 1997
- A Phase II trial of a high-dose weekly regimen of Bristol-MyersSquibb's Taxol (paclitaxel) has resulted in the highest-reported response rates ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
